NASDAQ: STTKShattuck Labs Inc Stock
$9.90+0.41 (+4.32%)
Updated Apr 24, 2024
STTK Price
$9.90
Fair Value Price
$1.84
Market Cap
$470.00M
52 Week Low
$1.33
52 Week High
$11.11
P/E
-4.83x
P/B
3.25x
P/S
183.31x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.66M
Earnings
-$87.30M
Gross Margin
100%
Operating Margin
-5,268.44%
Profit Margin
-5,268.4%
Debt to Equity
0.1
Operating Cash Flow
-$81M
Beta
1.17
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
STTK Overview
Shattuck Labs Incorporated is a clinical-stage biotechnology company developing bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune diseases. The company's lead program, SL-172154, designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is undergoing a Phase 1 trial. A second compound, SL-279252, is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Shattuck Labs was incorporated in 2016 and is headquartered in Austin, TX.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how STTK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
STTK ($9.90) is overvalued by 437.37% relative to our estimate of its Fair Value price of $1.84 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
STTK ($9.90) is not significantly undervalued (437.37%) relative to our estimate of its Fair Value price of $1.84 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
STTK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more STTK due diligence checks available for Premium users.
Be the first to know about important STTK news, forecast changes, insider trades & much more!
STTK News
Valuation
STTK fair value
Fair Value of STTK stock based on Discounted Cash Flow (DCF)
Price
$9.90
Fair Value
$1.84
Overvalued by
437.37%
STTK ($9.90) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
STTK ($9.90) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
STTK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
STTK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.83x
Industry
15.69x
Market
41.27x
STTK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.25x
Industry
5.86x
STTK is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
STTK's financial health
Profit margin
Revenue
$714.0k
Net Income
-$17.7M
Profit Margin
-2,477.2%
STTK's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
STTK's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$159.6M
Liabilities
$14.9M
Debt to equity
0.1
STTK's short-term assets ($143.22M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
STTK's short-term assets ($143.22M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
STTK's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
STTK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$19.4M
Investing
$55.9M
Financing
$48.6M
STTK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
STTK vs Biotech Stocks
Shattuck Labs Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.